A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus bioma...
Gespeichert in:
| Veröffentlicht in: | Heliyon Jg. 7; H. 3; S. e06438 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.03.2021
Elsevier |
| Schlagworte: | |
| ISSN: | 2405-8440, 2405-8440 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30–25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic.
Biomarker, Immunotherapy, Immune checkpoint inhibitors, NSCLC, TNBC, Tumor microenvironment. |
|---|---|
| AbstractList | Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30-25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic. Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30–25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic. Biomarker, Immunotherapy, Immune checkpoint inhibitors, NSCLC, TNBC, Tumor microenvironment. Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30–25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic. Biomarker, Immunotherapy, Immune checkpoint inhibitors, NSCLC, TNBC, Tumor microenvironment. Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30-25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic.Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (TME) may be more likely to respond, and thus biomarkers capable of discerning an active from a quiescent TME may be useful in patient selection. We developed an algorithm optimized for genes expressed in the mesenchymal and immunomodulatory subtypes of a 101-gene triple negative breast cancer model (Ring, BMC Cancer, 2016, 16:143) as a means to capture the immunological state of the TME. We compared the outcome of the algorithm (IO score) with the 101-gene model and found 88% concordance, indicating the models are correlated but not identical, and may be measuring different TME features. We found 92.5% correlation between IO scores of matched tumor epithelial and adjacent stromal tissues, indicating the IO score is not specific to these tissues, but reflects the TME as a whole. We observed a significant difference in IO score (p = 0.0092) between samples with high tumor-infiltrating lymphocytes and samples with increased neutrophil load, demonstrating agreement between IO score and these two prognostic markers. Finally, among non-small cell lung cancer patients receiving immunotherapy, we observed a significant difference in IO score (p = 0.0035) between responders and non-responders, and a significant odds ratio (OR = 5.76, 95% CI 1.30-25.51, p = 0.021), indicating the IO score can predict patient response. The immuno-oncology algorithm may offer independent and incremental predictive value over current biomarkers in the clinic. |
| ArticleNumber | e06438 |
| Author | Nielsen, Tyler J. Ring, Brian Z. Schweitzer, Brock L. Seitz, Robert S. Hout, David R. |
| Author_xml | – sequence: 1 givenname: Tyler J. orcidid: 0000-0002-9576-2838 surname: Nielsen fullname: Nielsen, Tyler J. email: tnielsen@oncocyte.com organization: Oncocyte Corporation, 2 International Drive, Suite 510, Nashville, TN 37217, USA – sequence: 2 givenname: Brian Z. orcidid: 0000-0003-4503-2690 surname: Ring fullname: Ring, Brian Z. organization: Hyperion Health, 950 Metro Center, Foster City, CA 94404, USA – sequence: 3 givenname: Robert S. orcidid: 0000-0002-5806-2840 surname: Seitz fullname: Seitz, Robert S. organization: Oncocyte Corporation, 2 International Drive, Suite 510, Nashville, TN 37217, USA – sequence: 4 givenname: David R. orcidid: 0000-0001-8897-3963 surname: Hout fullname: Hout, David R. organization: Oncocyte Corporation, 2 International Drive, Suite 510, Nashville, TN 37217, USA – sequence: 5 givenname: Brock L. orcidid: 0000-0003-0178-5594 surname: Schweitzer fullname: Schweitzer, Brock L. organization: Oncocyte Corporation, 2 International Drive, Suite 510, Nashville, TN 37217, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33748492$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1v1DAQhiNUREvpTwDlyCWLHX8lQgJVFbSVKnGBs-XYk6xXib3Yzkr773HIUrVcerI1M-8z9sz7tjhz3kFRvMdogxHmn3abLYz26N2mRjXeAOKUNK-Ki5oiVjWUorMn9_PiKsYdQgizhreCvCnOCRG0oW19Udjr0vkDjKWdptn5yjvtRz8cSzUOPti0ncoJVJyDdUOZ5smHcrI6eHAHG7ybwKUy-XIfwFidygBx712EJbYS0xaC2luI74rXvRojXJ3Oy-LX928_b-6qhx-39zfXD5VmnKeK1bxhrKVKMU6pEsCYMQIbxDrNRCc07RFFYFphOoq7rs9JVRvDTMvaFvfksrhfucarndwHO6lwlF5Z-TfgwyBVSFaPIFmjjECYYKwJ7bRuOUeCmDwaTQwyLLO-rKz93E1gdP5tUOMz6POMs1s5-IMUbebSBfDxBAj-9wwxyclGDeOoHPg5ypohwrlABOXSD097PTb5t6tcwNaCPP4YA_SPJRjJxRZyJ0-2kIst5GqLrPv8n07bpJL1y5Pt-KL666qGvLODhSCjtuB03ncAnfJQ7QuEP2cY2p8 |
| CitedBy_id | crossref_primary_10_1002_aisy_202400717 crossref_primary_10_1007_s12010_024_04948_w crossref_primary_10_1016_j_breast_2023_03_014 crossref_primary_10_1158_1078_0432_CCR_22_3878 crossref_primary_10_1136_jitc_2023_007126 crossref_primary_10_1158_1078_0432_CCR_24_0149 crossref_primary_10_1186_s12967_022_03563_9 crossref_primary_10_1016_j_breast_2025_104545 crossref_primary_10_1038_s41598_024_83915_1 crossref_primary_10_1007_s12609_025_00575_4 crossref_primary_10_3390_diagnostics12010124 crossref_primary_10_1007_s00262_023_03401_x crossref_primary_10_1186_s12885_022_09470_y crossref_primary_10_1016_j_cllc_2022_11_009 crossref_primary_10_1038_s41523_023_00541_2 crossref_primary_10_3389_fimmu_2024_1397469 crossref_primary_10_3390_cancers13194839 crossref_primary_10_1177_17588359211010156 |
| Cites_doi | 10.1158/1078-0432.CCR-16-3063 10.1093/biostatistics/kxj037 10.3390/ijms20081915 10.1016/S1470-2045(16)30406-5 10.3389/fimmu.2020.00223 10.1016/j.ejca.2016.03.081 10.1158/2326-6066.CIR-14-0209 10.3390/ijms20174305 10.1038/s41568-019-0116-x 10.1007/s10549-014-3185-2 10.3389/fonc.2018.00315 10.1186/s12885-016-2198-0 10.3390/cancers12030738 10.1073/pnas.0506580102 10.1101/cshperspect.a026781 10.1038/s41467-019-12159-9 10.1186/s40425-017-0300-z 10.3389/fimmu.2019.01710 10.2147/OTT.S153290 10.1093/annonc/mdx755 10.1001/jamanetworkopen.2019.2535 10.14639/0392-100X-2481 10.1186/s13073-020-00722-9 10.1155/2016/6058147 10.1038/s41591-018-0014-x 10.1371/journal.pone.0157368 10.1056/NEJMra1703481 |
| ContentType | Journal Article |
| Copyright | 2021 The Author(s) 2021 The Author(s). 2021 The Author(s) 2021 |
| Copyright_xml | – notice: 2021 The Author(s) – notice: 2021 The Author(s). – notice: 2021 The Author(s) 2021 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.heliyon.2021.e06438 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2405-8440 |
| ExternalDocumentID | oai_doaj_org_article_58ad701311c34bcc966073d484c3d0d5 PMC7970145 33748492 10_1016_j_heliyon_2021_e06438 S2405844021005430 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 457 53G 5VS 6I. AAEDW AAFTH AAFWJ AALRI AAYWO ABMAC ACGFS ACLIJ ACVFH ADBBV ADCNI ADEZE ADVLN AEUPX AEXQZ AFJKZ AFPKN AFPUW AFTJW AGHFR AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV DIK EBS EJD FDB GROUPED_DOAJ HYE IPNFZ KQ8 M~E O9- OK1 RIG ROL RPM SSZ AAYXX CITATION 0SF AACTN NCXOZ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c566t-52685594aa5644a7e55dd71d05bc57b7c4f040ed97db41bbfd71a2dd5d95991f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000637839600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2405-8440 |
| IngestDate | Fri Oct 03 12:51:49 EDT 2025 Tue Sep 30 17:12:45 EDT 2025 Thu Oct 02 05:21:59 EDT 2025 Thu Jan 02 22:56:23 EST 2025 Wed Nov 05 20:33:06 EST 2025 Tue Nov 18 22:16:27 EST 2025 Sat Nov 29 17:15:47 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Biomarker Immune checkpoint inhibitors NSCLC Tumor microenvironment TNBC Immunotherapy |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c566t-52685594aa5644a7e55dd71d05bc57b7c4f040ed97db41bbfd71a2dd5d95991f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9576-2838 0000-0003-0178-5594 0000-0002-5806-2840 0000-0001-8897-3963 0000-0003-4503-2690 |
| OpenAccessLink | https://doaj.org/article/58ad701311c34bcc966073d484c3d0d5 |
| PMID | 33748492 |
| PQID | 2503667030 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_58ad701311c34bcc966073d484c3d0d5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7970145 proquest_miscellaneous_2503667030 pubmed_primary_33748492 crossref_primary_10_1016_j_heliyon_2021_e06438 crossref_citationtrail_10_1016_j_heliyon_2021_e06438 elsevier_sciencedirect_doi_10_1016_j_heliyon_2021_e06438 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Heliyon |
| PublicationTitleAlternate | Heliyon |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Lehmann (bib13) 2016; 11 (bib15) 2019 Hirata, Sahai (bib30) 2017; 7 Haslam, Prasad (bib28) 2019; 2 Ibrahim (bib24) 2014; 148 Kim (bib23) 2020; 12 Zemek (bib29) 2020; 11 Havel, Chowell, Chan (bib3) 2019; 19 Butturini (bib11) 2019; 20 Grigoriadis (bib14) 2016 Granot (bib25) 2019; 10 R Core Team (bib16) 2020 Vaddepally (bib2) 2020; 12 Gibney, Weiner, Atkins (bib7) 2016; 17 Subramanian (bib18) 2005; 102 Jung (bib22) 2019; 10 Postow, Sidlow, Hellmann (bib5) 2018; 378 Hajian-Tilaki (bib20) 2013; 4 Wojas-Krawczyk (bib9) 2019; 20 Marshall, Djamgoz (bib4) 2018; 8 Kim, Bae (bib31) 2016; 2016 Mehnert (bib8) 2017; 23 Merlano (bib32) 2019; 39 Ring (bib12) 2016; 16 Puzanov (bib6) 2017; 5 Binnewies (bib10) 2018; 24 Sacdalan, Lucero, Sacdalan (bib26) 2018; 11 Schwartz (bib21) 2016; 62 Friedman, Hastie, Tibshirani (bib19) 2010; 33 Tang, Shalabi, Hubbard-Lucey (bib1) 2018; 29 Siegel, Miller, Jemal (bib27) 2020; 70 Dvorak (bib33) 2015; 3 Johnson, Li, Rabinovic (bib17) 2007; 8 Butturini (10.1016/j.heliyon.2021.e06438_bib11) 2019; 20 Wojas-Krawczyk (10.1016/j.heliyon.2021.e06438_bib9) 2019; 20 Ring (10.1016/j.heliyon.2021.e06438_bib12) 2016; 16 Hajian-Tilaki (10.1016/j.heliyon.2021.e06438_bib20) 2013; 4 Havel (10.1016/j.heliyon.2021.e06438_bib3) 2019; 19 Grigoriadis (10.1016/j.heliyon.2021.e06438_bib14) 2016 Merlano (10.1016/j.heliyon.2021.e06438_bib32) 2019; 39 Postow (10.1016/j.heliyon.2021.e06438_bib5) 2018; 378 Kim (10.1016/j.heliyon.2021.e06438_bib31) 2016; 2016 Dvorak (10.1016/j.heliyon.2021.e06438_bib33) 2015; 3 Puzanov (10.1016/j.heliyon.2021.e06438_bib6) 2017; 5 Schwartz (10.1016/j.heliyon.2021.e06438_bib21) 2016; 62 Kim (10.1016/j.heliyon.2021.e06438_bib23) 2020; 12 Granot (10.1016/j.heliyon.2021.e06438_bib25) 2019; 10 Binnewies (10.1016/j.heliyon.2021.e06438_bib10) 2018; 24 Siegel (10.1016/j.heliyon.2021.e06438_bib27) 2020; 70 Zemek (10.1016/j.heliyon.2021.e06438_bib29) 2020; 11 R Core Team (10.1016/j.heliyon.2021.e06438_bib16) 2020 Hirata (10.1016/j.heliyon.2021.e06438_bib30) 2017; 7 Ibrahim (10.1016/j.heliyon.2021.e06438_bib24) 2014; 148 Johnson (10.1016/j.heliyon.2021.e06438_bib17) 2007; 8 Jung (10.1016/j.heliyon.2021.e06438_bib22) 2019; 10 Marshall (10.1016/j.heliyon.2021.e06438_bib4) 2018; 8 Tang (10.1016/j.heliyon.2021.e06438_bib1) 2018; 29 Gibney (10.1016/j.heliyon.2021.e06438_bib7) 2016; 17 (10.1016/j.heliyon.2021.e06438_bib15) 2019 Friedman (10.1016/j.heliyon.2021.e06438_bib19) 2010; 33 Lehmann (10.1016/j.heliyon.2021.e06438_bib13) 2016; 11 Haslam (10.1016/j.heliyon.2021.e06438_bib28) 2019; 2 Vaddepally (10.1016/j.heliyon.2021.e06438_bib2) 2020; 12 Subramanian (10.1016/j.heliyon.2021.e06438_bib18) 2005; 102 Sacdalan (10.1016/j.heliyon.2021.e06438_bib26) 2018; 11 Mehnert (10.1016/j.heliyon.2021.e06438_bib8) 2017; 23 |
| References_xml | – volume: 4 start-page: 627 year: 2013 end-page: 635 ident: bib20 article-title: Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation publication-title: Caspian J. Intern. Med. – volume: 11 start-page: 223 year: 2020 ident: bib29 article-title: Sensitizing the tumor microenvironment to immune checkpoint therapy publication-title: Front. Immunol. – volume: 2016 start-page: 6058147 year: 2016 ident: bib31 article-title: Tumor-associated macrophages and neutrophils in tumor microenvironment publication-title: Mediat. Inflamm. – year: 2016 ident: bib14 article-title: Mesenchymal Subtype Negatively Associates with the Presence of Immune Infiltrates within a Triple Negative Breast Cancer Classifier – volume: 7 year: 2017 ident: bib30 article-title: Tumor microenvironment and differential responses to therapy publication-title: Cold Spring Harb. Perspect. Med. – volume: 11 start-page: 955 year: 2018 end-page: 965 ident: bib26 article-title: Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis publication-title: OncoTargets Ther. – volume: 20 year: 2019 ident: bib11 article-title: Tumor dormancy and interplay with hypoxic tumor microenvironment publication-title: Int. J. Mol. Sci. – volume: 33 start-page: 1 year: 2010 end-page: 22 ident: bib19 article-title: Regularization paths for generalized linear models via coordinate descent publication-title: J. Stat. Software – volume: 20 year: 2019 ident: bib9 article-title: Beyond PD-L1 markers for lung cancer immunotherapy publication-title: Int. J. Mol. Sci. – volume: 39 start-page: 2 year: 2019 end-page: 8 ident: bib32 article-title: Knowing the tumour microenvironment to optimise immunotherapy publication-title: Acta Otorhinolaryngol. Ital. – volume: 8 start-page: 118 year: 2007 end-page: 127 ident: bib17 article-title: Adjusting batch effects in microarray expression data using empirical Bayes methods publication-title: Biostatistics – year: 2019 ident: bib15 article-title: RStudio: Integrated Development for R – volume: 12 year: 2020 ident: bib2 article-title: Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence publication-title: Cancers – year: 2020 ident: bib16 article-title: A Language and Environment for Statistical Computing – volume: 24 start-page: 541 year: 2018 end-page: 550 ident: bib10 article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy publication-title: Nat. Med. – volume: 102 start-page: 15545 year: 2005 end-page: 15550 ident: bib18 article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 70 start-page: 7 year: 2020 end-page: 30 ident: bib27 article-title: Cancer statistics, 2020 publication-title: CA A Cancer J. Clin. – volume: 2 year: 2019 ident: bib28 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open – volume: 12 start-page: 22 year: 2020 ident: bib23 article-title: Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer publication-title: Genome Med. – volume: 5 start-page: 95 year: 2017 ident: bib6 article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group publication-title: J. Immunother. Cancer – volume: 19 start-page: 133 year: 2019 end-page: 150 ident: bib3 article-title: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy publication-title: Nat. Rev. Canc. – volume: 378 start-page: 158 year: 2018 end-page: 168 ident: bib5 article-title: Immune-related adverse events associated with immune checkpoint blockade publication-title: N. Engl. J. Med. – volume: 10 start-page: 1710 year: 2019 ident: bib25 article-title: Neutrophils as a therapeutic target in cancer publication-title: Front. Immunol. – volume: 3 start-page: 1 year: 2015 end-page: 11 ident: bib33 article-title: Tumors: wounds that do not heal-redux publication-title: Cancer Immunol. Res. – volume: 23 start-page: 4970 year: 2017 end-page: 4979 ident: bib8 article-title: The challenge for development of valuable immuno-oncology biomarkers publication-title: Clin. Cancer Res. – volume: 10 start-page: 4278 year: 2019 ident: bib22 article-title: DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load publication-title: Nat. Commun. – volume: 17 start-page: e542 year: 2016 end-page: e551 ident: bib7 article-title: Predictive biomarkers for checkpoint inhibitor-based immunotherapy publication-title: Lancet Oncol. – volume: 8 start-page: 315 year: 2018 ident: bib4 article-title: Immuno-oncology: emerging targets and combination therapies publication-title: Front. Oncol. – volume: 148 start-page: 467 year: 2014 end-page: 476 ident: bib24 article-title: The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis publication-title: Breast Canc. Res. Treat. – volume: 62 start-page: 132 year: 2016 end-page: 137 ident: bib21 article-title: RECIST 1.1-Update and clarification: from the RECIST committee publication-title: Eur. J. Canc. – volume: 29 start-page: 84 year: 2018 end-page: 91 ident: bib1 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. – volume: 16 start-page: 143 year: 2016 ident: bib12 article-title: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients publication-title: BMC Canc. – volume: 11 year: 2016 ident: bib13 article-title: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection publication-title: PloS One – volume: 23 start-page: 4970 issue: 17 year: 2017 ident: 10.1016/j.heliyon.2021.e06438_bib8 article-title: The challenge for development of valuable immuno-oncology biomarkers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-3063 – volume: 8 start-page: 118 issue: 1 year: 2007 ident: 10.1016/j.heliyon.2021.e06438_bib17 article-title: Adjusting batch effects in microarray expression data using empirical Bayes methods publication-title: Biostatistics doi: 10.1093/biostatistics/kxj037 – volume: 20 issue: 8 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib9 article-title: Beyond PD-L1 markers for lung cancer immunotherapy publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20081915 – volume: 17 start-page: e542 issue: 12 year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib7 article-title: Predictive biomarkers for checkpoint inhibitor-based immunotherapy publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30406-5 – volume: 11 start-page: 223 year: 2020 ident: 10.1016/j.heliyon.2021.e06438_bib29 article-title: Sensitizing the tumor microenvironment to immune checkpoint therapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.00223 – volume: 62 start-page: 132 year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib21 article-title: RECIST 1.1-Update and clarification: from the RECIST committee publication-title: Eur. J. Canc. doi: 10.1016/j.ejca.2016.03.081 – volume: 3 start-page: 1 issue: 1 year: 2015 ident: 10.1016/j.heliyon.2021.e06438_bib33 article-title: Tumors: wounds that do not heal-redux publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0209 – volume: 20 issue: 17 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib11 article-title: Tumor dormancy and interplay with hypoxic tumor microenvironment publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20174305 – volume: 19 start-page: 133 issue: 3 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib3 article-title: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy publication-title: Nat. Rev. Canc. doi: 10.1038/s41568-019-0116-x – volume: 148 start-page: 467 issue: 3 year: 2014 ident: 10.1016/j.heliyon.2021.e06438_bib24 article-title: The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis publication-title: Breast Canc. Res. Treat. doi: 10.1007/s10549-014-3185-2 – volume: 8 start-page: 315 year: 2018 ident: 10.1016/j.heliyon.2021.e06438_bib4 article-title: Immuno-oncology: emerging targets and combination therapies publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00315 – volume: 16 start-page: 143 year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib12 article-title: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients publication-title: BMC Canc. doi: 10.1186/s12885-016-2198-0 – volume: 12 issue: 3 year: 2020 ident: 10.1016/j.heliyon.2021.e06438_bib2 article-title: Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence publication-title: Cancers doi: 10.3390/cancers12030738 – volume: 102 start-page: 15545 issue: 43 year: 2005 ident: 10.1016/j.heliyon.2021.e06438_bib18 article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0506580102 – volume: 7 issue: 7 year: 2017 ident: 10.1016/j.heliyon.2021.e06438_bib30 article-title: Tumor microenvironment and differential responses to therapy publication-title: Cold Spring Harb. Perspect. Med. doi: 10.1101/cshperspect.a026781 – volume: 33 start-page: 1 issue: 1 year: 2010 ident: 10.1016/j.heliyon.2021.e06438_bib19 article-title: Regularization paths for generalized linear models via coordinate descent publication-title: J. Stat. Software – volume: 10 start-page: 4278 issue: 1 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib22 article-title: DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load publication-title: Nat. Commun. doi: 10.1038/s41467-019-12159-9 – year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib15 – volume: 5 start-page: 95 issue: 1 year: 2017 ident: 10.1016/j.heliyon.2021.e06438_bib6 article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group publication-title: J. Immunother. Cancer doi: 10.1186/s40425-017-0300-z – volume: 10 start-page: 1710 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib25 article-title: Neutrophils as a therapeutic target in cancer publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.01710 – volume: 70 start-page: 7 issue: 1 year: 2020 ident: 10.1016/j.heliyon.2021.e06438_bib27 article-title: Cancer statistics, 2020 publication-title: CA A Cancer J. Clin. – volume: 11 start-page: 955 year: 2018 ident: 10.1016/j.heliyon.2021.e06438_bib26 article-title: Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis publication-title: OncoTargets Ther. doi: 10.2147/OTT.S153290 – volume: 29 start-page: 84 issue: 1 year: 2018 ident: 10.1016/j.heliyon.2021.e06438_bib1 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx755 – volume: 2 issue: 5 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib28 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 – year: 2020 ident: 10.1016/j.heliyon.2021.e06438_bib16 – volume: 39 start-page: 2 issue: 1 year: 2019 ident: 10.1016/j.heliyon.2021.e06438_bib32 article-title: Knowing the tumour microenvironment to optimise immunotherapy publication-title: Acta Otorhinolaryngol. Ital. doi: 10.14639/0392-100X-2481 – volume: 12 start-page: 22 issue: 1 year: 2020 ident: 10.1016/j.heliyon.2021.e06438_bib23 article-title: Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer publication-title: Genome Med. doi: 10.1186/s13073-020-00722-9 – volume: 2016 start-page: 6058147 year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib31 article-title: Tumor-associated macrophages and neutrophils in tumor microenvironment publication-title: Mediat. Inflamm. doi: 10.1155/2016/6058147 – volume: 24 start-page: 541 issue: 5 year: 2018 ident: 10.1016/j.heliyon.2021.e06438_bib10 article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy publication-title: Nat. Med. doi: 10.1038/s41591-018-0014-x – year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib14 – volume: 11 issue: 6 year: 2016 ident: 10.1016/j.heliyon.2021.e06438_bib13 article-title: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection publication-title: PloS One doi: 10.1371/journal.pone.0157368 – volume: 4 start-page: 627 issue: 2 year: 2013 ident: 10.1016/j.heliyon.2021.e06438_bib20 article-title: Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation publication-title: Caspian J. Intern. Med. – volume: 378 start-page: 158 issue: 2 year: 2018 ident: 10.1016/j.heliyon.2021.e06438_bib5 article-title: Immune-related adverse events associated with immune checkpoint blockade publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1703481 |
| SSID | ssj0001586973 |
| Score | 2.277304 |
| Snippet | Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e06438 |
| SubjectTerms | Biomarker Immune checkpoint inhibitors Immunotherapy NSCLC TNBC Tumor microenvironment |
| Title | A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies |
| URI | https://dx.doi.org/10.1016/j.heliyon.2021.e06438 https://www.ncbi.nlm.nih.gov/pubmed/33748492 https://www.proquest.com/docview/2503667030 https://pubmed.ncbi.nlm.nih.gov/PMC7970145 https://doaj.org/article/58ad701311c34bcc966073d484c3d0d5 |
| Volume | 7 |
| WOSCitedRecordID | wos000637839600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2405-8440 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001586973 issn: 2405-8440 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2405-8440 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001586973 issn: 2405-8440 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4t0UqIzE1ds4sWP7WFArDrTiAGhvll9hU-0mVZqt1Au_vX5klw0c9sIlBzt2Ys9MZiae-QaAj0xzom0lkMWaI4KJQ8I6gXRZk9xiZqpYee7nV3Z5yedz8W2n1FeICUvwwGnjTihXlkVQGFMSbUxAk2SlJZyY0uY2opfmTOw4Uyk_mFciHi97jUURJyT_k75zcjVbuGVz1wX80wLPXFDLfKKYIn7_RD_9a3_-HUa5o5fOn4Gno0EJT9NCnoMHrn0BHl-MR-YvQXMK2-7WLWETMkE61LURp_oOquWvrm-GxQqu4n9Cr8PgsF51PVyFIL2dDDg4dPC6DzMOsE8xtS60pRlTBpd3uF-BH-dn3z9_QWN9BWS8ETeggPTiHQqiFPVWkWKOUmsZtjnVhjLNDKm9iDsrmNUEa137TlVYS62g3qysy9fgoO1adwig1_zGS75nS-9wUleJGhcaK8yFKl1Z5Bkgm82VZgQfDzUwlnITZXYlR5rIQBOZaJKB2XbYdULf2DfgU6Dc9uYAnh0bPEvJkaXkPpbKAN_QXY52SLIv_FTNvud_2PCJ9HIaDl9U67r1jfSmZllV4fuagTeJb7ZvWQYMICKKDLAJR02WMe1pm0XEAmeChYPho_-x7rfgSVhKirB7Bw6Gfu3eg0fmdmhu-mPwkM35cRQzf734fXYPDkQumQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+immuno-oncology+algorithm+measuring+tumor+microenvironment+to+predict+response+to+immunotherapies&rft.jtitle=Heliyon&rft.au=Nielsen%2C+Tyler+J&rft.au=Ring%2C+Brian+Z&rft.au=Seitz%2C+Robert+S&rft.au=Hout%2C+David+R&rft.date=2021-03-01&rft.issn=2405-8440&rft.eissn=2405-8440&rft.volume=7&rft.issue=3&rft.spage=e06438&rft_id=info:doi/10.1016%2Fj.heliyon.2021.e06438&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-8440&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-8440&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-8440&client=summon |